HENDERSON, NV / ACCESSWIRE / November 7, 2018 / Midterm elections are expected to result in a split Congress, which should increase predictability for the biotech industry, and prevent, what some see as disruptive, government dictated pricing, less likely than if there is a Congress controlled by one party.
Propanc Biopharma, Inc. (PPCB) is one biotech firm you should look at today. The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE). Benefits of ODE include the potential for the following, tax credits of up to 50% of R&D expenditures, R&D grants, waivers of some FDA fees, and protocol assistance by the FDA.
The company is also very close to its first-in-human studies. Start your research on PPCB immediately.
Some biotech and pharma stocks to watch include: Propanc Biopharma, Inc. (PPCB), Titan Pharmaceuticals, Inc. (TTNP), Aytu BioScience, Inc. (AYTU), CorMedix, Inc. (CRMD), and Puma Biotechnology, Inc. (PBYI).
Propanc Biopharma, Inc. (PPCB)
Market Cap: $9.01M Share Price: $0.05
Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, announced on (insert date) initiation of European (EP) validation of its lead patent in most major commercial markets in Europe. EP validation is the process of converting a single granted European patent application into a national patent in one or more contracting member and extension states of the European Patent Convention.
The Company's lead patent, which describes a pharmaceutical composition for treating cancer, is currently undergoing validation in 14 European countries - Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Once validated, the Company will have the rights associated with a granted patent in each of these 14 European countries.
Titan Pharmaceuticals, Inc. (TTNP)
Market Cap: $32.84M Share Price: $0.51
Titan Pharmaceuticals develops proprietary therapeutics for the treatment of select chronic diseases. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. Last month, Knight Therapeutics Inc. (GUD) announced the commercial availability of PROBUPHINE™ (buprenorphine hydrochloride subdermal implant), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support. Knight has the exclusive right to distribute PROBUPHINE in Canada under a license agreement with Titan Pharmaceuticals, Inc.
Aytu BioScience, Inc. (AYTU)
Market Cap: $13.35M Share Price: $1.26
Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, announced the Company's entry into the $3 billion cough and cold market with an exclusive license of FDA-approved Tuzistra® XR from Tris Pharma. Tuzistra XR is the only FDA-approved 12-hour codeine-based antitussive. Tuzistra XR is a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an extended-release oral suspension.
CorMedix, Inc. (CRMD)
Market Cap: $137.77M Share Price: $1.37
Earlier in October, CorMedix clarified its share structure. Specifically, the company clarified that contrary to certain erroneous news reports it is not issuing any new shares in connection with the S-3 filing filed on October 15, 2018.
On October 15, 2018, the Company filed a Form S-3 registration statement to register an aggregate of 15,081,634 shares of its common stock issuable upon the exercise of Series B warrants with an exercise price of $1.05 and associated Underwriter warrants with an exercise price of $0.9375, both expiring on August 10, 2022, which were issued in connection with the Company's May 2017 underwritten public offering.
Puma Biotechnology, Inc. (PBYI)
Market Cap: $852.96M Share Price: $22.30
PBYI recently conducted an Earnings call discussing a positive report of sales of NERLYNX, also known as neratinib, Puma's first approved drug. Sales have grown since launch. NERLYNX was approved by the US FDA in July 2017 for the treatment of patients with early-stage HER2-positive breast cancer, who have previously been treated with a trastuzumab-containing regimen. The company reported NERLYNX's net sales of $52.6 million for the third quarter of 2018, an increase from the $50.8 million in net sales reported in the second quarter of 2018. In addition, third quarter results included licensing revenue of $10 million, which represented an upfront payment we received from one of our licensing partners.
Important Disclaimer, Please Read:
The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.
The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.
Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. PPCB expects to pay forty thousand dollars for corporate awareness services for the month of November, and expects to continue to pay Regal to disseminate truthful and potentially material information regarding PPCB.
Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.
Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.
Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in PPCB can be found updated here: http://www.regalconsultingllc.com/disclaimer/.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and ninety-seven thousand two hundred dollars total by Regal Consulting. LLC, for news commentary articles for PPCB. Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of PPCB in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC, For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC